PR Newswire
LONDON, United Kingdom, October 10
10 October 2025
4basebio PLC
("4basebio" or the "Company")
Result of Extraordinary General Meeting
Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed.
For further enquiries, please contact:
| 4basebio PLC | +44 (0)12 2396 7943 |
| Dr. Heikki Lanckriet, CEO |
|
| Cairn Financial Advisers LLP (Nominated Adviser ) | +44 (0)20 7213 0880 |
| Jo Turner / Sandy Jamieson / Ed Downes |
|
| Cavendish Capital Markets Limited ( Joint Broker) | +44 (0)20 7220 0500 |
| Geoff Nash / Nigel Birks |
|
| RBC Capital Markets (Joint Broker) | +44 (0) 20 7653 4000 |
| Kathryn Deegan / Matthew Coakes |
|
Notes to Editors
About 4basebio
4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.
